Intestinal response to growth factors administered alone or in combination with human [Gly2]glucagon-like peptide 2.

No abstract is available for this paper.

• Publication year

  1997

• Venue

  American Journal of Physiology

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1152/ajpgi.1997.273.6.G1252PMID 9435550
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Regulation of the biological activity of glucagon-like peptide 2 in vivo by dipeptidyl peptidase IV

  1997cited by this paper
• Systemic infusion of IGF-I or LR(3)IGF-I stimulates visceral organ growth and proliferation of gut tissues in suckling rats.

  1997cited by this paper
• Biological determinants of intestinotrophic properties of GLP-2 in vivo.

  1997cited by this paper
• Delayed effects of epidermal growth factor after extensive small bowel resection

  1997cited by this paper
• Enhanced growth of small bowel in transgenic mice expressing human insulin-like growth factor I.

  1997cited by this paper
• Intestinal growth-promoting properties of glucagon-like peptide-2 in mice.

  1997cited by this paper
• Intestinal function in mice with small bowel growth induced by glucagon-like peptide-2.

  1997cited by this paper
• Growth hormone did not enhance mucosal hyperplasia after small-bowel resection.

  1996cited by this paper
• Induction of intestinal epithelial proliferation by glucagon-like peptide 2.

  1996cited by this paper
• Beneficial effects of insulin-like growth factor I on epithelial structure and function in parenterally fed rat jejunum.

  1996cited by this paper
• Acute epithelial injury in the rat small intestine in vivo is associated with expanded expression of transforming growth factor alpha and beta.

  1996cited by this paper
• Role of prohormone convertases in the tissue-specific processing of proglucagon.

  1996cited by this paper
• Delayed effects of epidermal growth factor after extensive small bowel resection.

  1996cited by this paper
• Functional active receptors for insulin-like growth factors-I (IGF-I) and IGF-II on insulin-, glucagon-, and somatostatin-producing cells.

  1996cited by this paper
• Luminal epidermal growth factor preserves mucosal mass of small bowel in fasting rats.

  1996cited by this paper
• Regulation and localization of the insulin-like growth factor system in small bowel during altered nutrient status.

  1995cited by this paper
• Growth hormone, glutamine, and a modified diet enhance nutrient absorption in patients with severe short bowel syndrome.

  1995cited by this paper
• Continuous 14 day infusion of IGF-II increases the growth of normal female rats, but exhibits a lower potency than IGF-I.

  1995cited by this paper
• Luminal epidermal growth factor is trophic to the small intestine of parenterally fed rats.

  1995cited by this paper
• Chronic systemic treatment with epidermal growth factor in the rat increases the mucosal surface of the small intestine.

  1995cited by this paper
• Stimulation and inhibition of proliferation in the small intestinal crypts of the mouse after in vivo administration of growth factors.

  1995cited by this paper
• Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor

  1995cited by this paper
• Insulin-like growth factors and their binding proteins: biological actions.

  1995cited by this paper
• Protective effect of epidermal growth factor in an experimental model of colitis in rats.

  1994cited by this paper
• Consequences of postnatally elevated insulin-like growth factor-II in transgenic mice: endocrine changes and effects on body and organ growth.

  1994cited by this paper
• Inhibition of pancreatic proglucagon gene expression in mice bearing subcutaneous endocrine tumors.

  1994cited by this paper
• Prolonged administration of IGF peptides enhances growth of gastrointestinal tissues in normal rats.

  1994cited by this paper
• Disproportionate growth in mice with Igf-2 transgenes.

  1994cited by this paper
• Ileal proglucagon gene expression in the rat: characterization in intestinal adaptation using in situ hybridization.

  1993cited by this paper
• Enhanced growth of small bowel in transgenic mice overexpressing bovine growth hormone.

  1993cited by this paper
• Truncated and native insulinlike growth factor I enhance mucosal adaptation after jejunoileal resection.

  1992cited by this paper
• Insulin-like growth factor-I and its N-terminal modified analogues induce marked gut growth in dexamethasone-treated rats.

  1992cited by this paper
• Epidermal growth factor in necrotising enteritis.

  1991cited by this paper
• Production of transforming growth factor-alpha by normal rat small intestine.

  1991cited by this paper
• Ileal glucagon gene expression: ontogeny and response to massive small bowel resection.

  1990cited by this paper
• The effect of the route of delivery of urogastrone on intestinal regeneration.

  1989cited by this paper
• Influence of epidermal growth factor on intestinal function in the rat: comparison of systemic infusion versus luminal perfusion.

  1988cited by this paper
• The effect of epidermal growth factor (EGF) on cell proliferation of the gastrointestinal mucosa in rodents

  1982cited by this paper
• The hormonal pattern of intestinal adaptation. A major role for enteroglucagon.

  1982cited by this paper
• The hormonal pattern of intestinal adaptation. A major role for enteroglucagon.

  1982cited by this paper
• Gut hormone release after intestinal resection.

  1982cited by this paper
• Development of the small intestine in the hypophysectomized rat. I. Growth histology, and activity of alkaline phosphatase, maltase, and sucrase.

  1975cited by this paper

• Microbial activation of the GLP-2R mitigates gastrointestinal inflammation

  2026cites this paper
• Gut Hormones and Inflammatory Bowel Disease

  2025cites this paper
• Biased GLP‐2 agonist with strong G protein‐coupling but impaired arrestin recruitment and receptor desensitization enhances intestinal growth in mice

  2023cites this paper
• Long-acting agonists of human and rodent GLP-2 receptors for studies of the physiology and pharmacological potential of the GLP-2 system.

  2023cites this paper
• An updated overview of glucagon-like peptide-2 analog trophic therapy for short bowel syndrome in adults

  2022cites this paper
• Acute Low-Intensity Treadmill Running Upregulates the Expression of Intestinal Glucose Transporters via GLP-2 in Mice

  2021cites this paper
• Influence of Cane Molasses Inclusion to Dairy Cow Diets during the Transition Period on Rumen Epithelial Development

  2021cites this paper
• Site-Specific and Temporal Effects of Apraglutide, a Novel Long-Acting Glucagon-Like Peptide-2 Receptor Agonist, on Intestinal Growth in Mice

  2020cites this paper
• GLP-2, EGF and the intestinal epithelial IGF-1 receptor interactions in the regulation of crypt cell proliferation.

  2020cites this paper
• GLP-2 Acutely Prevents Endotoxin-Related Increased Intestinal Paracellular Permeability in Rats

  2020cites this paper
• Novel Long-Acting GLP-2 Analogue, FE 203799 (Apraglutide), Enhances Adaptation and Linear Intestinal Growth in a Neonatal Piglet Model of Short Bowel Syndrome with Total Resection of the Ileum.

  2019cites this paper
• Glucagon-Like Peptide-2 and the Enteric Nervous System Are Components of Cell-Cell Communication Pathway Regulating Intestinal Na+/Glucose Co-transport

  2018cites this paper
• Glucagon-like Peptide-2 and the Regulation of Intestinal Growth and Function.

  2018cites this paper
• rhIGF-1/rhIGFBP-3 in Preterm Infants: A Phase 2 Randomized Controlled Trial

  2018cites this paper
• Effects of exogenous glucagon-like peptide-2 and distal bowel resection on intestinal and systemic adaptive responses in rats

  2017cites this paper
• Pharmacological strategies to enhance adaptation in intestinal failure

  2016cites this paper
• Synthesis and Pharmacological Characterization of Novel Glucagon-like Peptide-2 (GLP-2) Analogues with Low Systemic Clearance.

  2016cites this paper
• Teduglutide for Safe Reduction of Parenteral Nutrient and/or Fluid Requirements in Adults: A Systematic Review.

  2016cites this paper
• On the horizon: trophic peptide growth factors as therapy for neonatal short bowel syndrome

  2016cites this paper
• Glucagon-like peptides 1 and 2: intestinal hormones implicated in the pathophysiology of mucositis

  2015cites this paper
• Stem cells and biopharmaceuticals: vital roles in the growth of tissue-engineered small intestine.

  2014cites this paper
• Effects of PEGylated porcine glucagon-like peptide-2 therapy in weaning piglets challenged with lipopolysaccharide.

  2014cites this paper
• Teduglutide Enhances Structural Adaptation of the Small Intestinal Mucosa in Patients With Short Bowel Syndrome

  2013influential citation
• Novel therapies for the management of short bowel syndrome in children

  2013cites this paper
• Glucagon-like peptide 2 increases efficacy of distraction enterogenesis.

  2013cites this paper
• Glucagon-like peptide 2 in colon carcinogenesis: possible target for anti-cancer therapy?

  2013cites this paper
• Review article: a comparison of glucagon‐like peptides 1 and 2

  2013cites this paper
• Nonruminant Nutrition Symposium: The role of glucagon-like peptide-2 in controlling intestinal function in human infants: regulator or bystander?

  2012cites this paper
• Glucagon-like peptide-2 (GLP-2) increases net amino acid utilization by the portal-drained viscera of ruminating calves.

  2012cites this paper
• GLP2-2G-XTEN: A Pharmaceutical Protein with Improved Serum Half-Life and Efficacy in a Rat Crohn’s Disease Model

  2012cites this paper
• Teduglutide for the treatment of short bowel syndrome

  2011cites this paper
• The "cryptic" mechanism of action of glucagon-like peptide-2.

  2011cites this paper
• Growth factors adsorbed on polyglycolic acid mesh augment growth of bioengineered intestinal neomucosa.

  2011cites this paper
• Dipeptidyl peptidase expression during experimental colitis in mice

  2010cites this paper
• The influence of nutrients, biliary-pancreatic secretions, and systemic trophic hormones on intestinal adaptation in a Roux-en-Y bypass model.

  2010cites this paper
• Short Bowel Patients Treated for Two Years with Glucagon-Like Peptide 2: Effects on Intestinal Morphology and Absorption, Renal Function, Bone and Body Composition, and Muscle Function

  2009cites this paper
• Short Bowel Patients Treated for Two Years with Glucagon-Like Peptide 2 (GLP-2): Compliance, Safety, and Effects on Quality of Life

  2009cites this paper
• Glucagon-like peptide-2 modulates neurally evoked mucosal chloride secretion in guinea pig small intestine in vitro.

  2009cites this paper
• Intestinal hormones and growth factors: effects on the small intestine.

  2009cites this paper
• Synergistic Effect of Glucagon-Like Peptide 2 (GLP-2) and of Key Growth Factors on the Proliferation of Cultured Rat Astrocytes. Evidence for Reciprocal Upregulation of the mRNAs for GLP-2 and IGF-I Receptors

  2009cites this paper
• Growth factor based therapies and intestinal disease: is glucagon-like peptide-2 the new way forward?

  2009cites this paper
• Glucagon-like peptide-2 activates beta-catenin signaling in the mouse intestinal crypt: role of insulin-like growth factor-I.

  2008cites this paper
• Life in the crypt: a role for glucagon-like peptide-2?

  2008cites this paper
• Review article: glucagon‐like peptide 2 – current applications and future directions

  2007cites this paper
• Enteric neural pathways mediate the anti-inflammatory actions of glucagon-like peptide 2.

  2007cites this paper
• Glucagon-like Peptide-2.

  2006cites this paper
• The role of polyamines in glucagon-like peptide-2 prevention of TPN-induced gut hypoplasia.

  2006cites this paper
• Gut hormones, and short bowel syndrome: the enigmatic role of glucagon-like peptide-2 in the regulation of intestinal adaptation.

  2006cites this paper
• The essential role of insulin-like growth factor-1 in the intestinal tropic effects of glucagon-like peptide-2 in mice.

  2006cites this paper
• Plasma concentrations of glucagon-like peptide-2 in adult patients with treated and untreated coeliac disease

  2006cites this paper
• Teduglutide for the Treatment of Short Bowel Syndrome

  2006cites this paper
• Glucagon-like peptide 2: an update

  2005cites this paper
• Intestinal adaptation after massive intestinal resection

  2005cites this paper
• Intestinal growth in parenterally-fed rats induced by the combined effects of glucagon-like peptide 2 and epidermal growth factor.

  2005cites this paper
• Insulin-like growth factor-I (IGF-I) attenuates jejunal atrophy in association with increased expression of IGF-I binding protein-5 in parenterally fed mice.

  2005cites this paper
• Mucosal adaptation to enteral nutrients is dependent on the physiologic actions of glucagon-like peptide-2 in mice.

  2005cites this paper
• Intestinal Adaptation in Short Bowel Syndrome

  2005cites this paper
• Glucagon-like peptide-2 induces intestinal adaptation in parenterally fed rats with short bowel syndrome.

  2004cites this paper
• Plasma GLP-2 Levels and Intestinal Markers in the Juvenile Pig During Intestinal Adaptation: Effects of Different Diet Regimens

  2004cites this paper
• Comparative effects of glucagon-like peptide-2 (GLP-2), growth hormone (GH), and keratinocyte growth factor (KGF) on markers of gut adaptation after massive small bowel resection in rats.

  2004cites this paper
• Teduglutide ([Gly2]GLP‐2) protects small intestinal stem cells from radiation damage

  2004cites this paper
• Intestinal Rehabilitation and the Short Bowel Syndrome: Part 1

  2004cites this paper
• Cell-Surface Peptidases

  2004cites this paper
• Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis.

  2003cites this paper
• The multifunctional or moonlighting protein CD26/DPPIV.

  2003cites this paper
• Dual regulation of cell proliferation and survival via activation of glucagon-like peptide-2 receptor signaling.

  2003cites this paper
• Glucagon-like Peptide-1 Receptor Signaling Modulates β Cell Apoptosis*

  2003cites this paper
• Genetic interaction between a maternal factor and the zygotic genome controls the intestine length in PRM/Alf mice.

  2003cites this paper
• International Union of Pharmacology. XXXV. The Glucagon Receptor Family

  2003cites this paper
• Glucagon-like peptide 2 function in domestic animals.

  2003cites this paper
• Role of gastrointestinal hormones in the proliferation of normal and neoplastic tissues.

  2003cites this paper
• The truncated metabolite GLP-2 (3-33) interacts with the GLP-2 receptor as a partial agonist.

  2002cites this paper
• Gut adaptation and the glucagon-like peptides

  2002cites this paper
• Influence of diet complexity on intestinal adaptation following massive small bowel resection in a preclinical model

  2002cites this paper
• Biological actions and therapeutic potential of the glucagon-like peptides.

  2002cites this paper
• GLP-2alpha accelerates recovery of mucosal absorptive function after intestinal ischemia/reperfusion.

  2001cites this paper
• Therapeutic potential of the intestinotropic hormone, glucagon-like peptide-2

  2001cites this paper
• Minireview: the glucagon-like peptides.

  2001cites this paper
• Pharmacotherapy and growth factors in the treatment of short bowel syndrome.

  2001cites this paper
• Structure and postresectional adaptation of the small bowel autotransplant : Experimental studies in pigs

  2001cites this paper
• Glucagon-like peptide-2 stimulates gut mucosal growth and immune response in burned rats.

  2001cites this paper
• Potential targets for glucagon-like peptide 2 (GLP-2) in the rat: distribution and binding of i.v. injected (125)I-GLP-2.

  2000cites this paper
• New Developments in the Biology of the Glucagon‐Like Peptides GLP‐1 and GLP‐2

  2000cites this paper
• Maintaining Gut Integrity During Parenteral Nutrition of Tumor-Bearing Rats: Effects of Glucagon-Like Peptide 2

  2000cites this paper
• Humoral factors in intestinal adaptation.

  2000cites this paper
• Ontogeny of the glucagon-like peptide-2 receptor axis in the developing rat intestine.

  2000cites this paper
• Glucagonlike peptide-2 analogue enhances intestinal mucosal mass after ischemia and reperfusion.

  2000cites this paper
• New frontiers in the biology of GLP-2.

  2000cites this paper
• Synthesis, secretion and biological actions of the glucagon‐like peptides

  2000cites this paper
• Glucagon-like peptide 2: a new treatment for chemotherapy-induced enteritis.

  2000cites this paper
• Glucagon-like peptide-2 increases sucrase-isomaltase but not caudal-related homeobox protein-2 gene expression.

  2000cites this paper
• Inhibition of sham feeding-stimulated human gastric acid secretion by glucagon-like peptide-2.

  1999cites this paper
• Dipeptidyl-peptidase IV (CD26)--role in the inactivation of regulatory peptides.

  1999cites this paper
• Cell proliferation in gastrointestinal mucosa.

  1999cites this paper
• Enterotrophic effects of glucagon-like peptide 2 are enhanced by neurotensin

  1999cites this paper
• The glucagon-like peptides.

  1999cites this paper
• Biologic properties and therapeutic potential of glucagon-like peptide-2.

  1999cites this paper
• mRNA levels of dipeptidyl peptidase IV decrease during intestinal adaptation.

  1999cites this paper
• Glucagon-like Peptide 2.

  1999cites this paper
• Prototypic G protein-coupled receptor for the intestinotrophic factor glucagon-like peptide 2.

  1999cites this paper